Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children

Memorial Sloan Kettering Cancer Center30 enrolled

Overview

The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Intraocular Retinoblastoma Hearing Loss

Interventions

Distortion product otoacoustic emission measurement (DPOAE)DIAGNOSTIC_TEST

Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.

Eligibility

Sex: ALLMin age: 3 MonthsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent indicating awareness of the investigational nature of the protocol. * Children with RB aged 3 months and older who are scheduled to receive their first dose of IA carboplatin chemotherapy. * Retinoblastoma is rarely seen in children over 8 years old, however we will not include an upper age range so as not to exclude any possible participants Exclusion Criteria: * Children with known and documented preexisting hearing loss.

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Outcomes

Primary Outcomes

Estimate the incidence of hearing loss

will be defined as a \>10 db loss from baseline in any frequency, based on the lower threshold of the American Speech and Hearing Associations (ASHA) hearing change criteria. For children unable to cooperate for an audiogram, the DPOAE will be the primary measurement.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.